NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

Download a CSV of all Patent records.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset Search to show all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-230-2012-0-HK-68 T Cell Receptors Recognizing MHC Class II-Restricted Mage-A3 HK CN 42022051280.0 Pending
NHLBI E-036-2022-0-US-01 SABRE CATALYSTS CONTAINING FLUORINATED CARBON CHAINS FOR DELIVERY OF METAL-FREE MRI CONTRAST AGENTS US 63/328,545 Expired
NIAID E-060-2022-0-US-01 BETA GLOBIN MIMETIC PEPTIDES AND THEIR USE US 63/328,615 Expired
NHLBI E-052-2022-0-US-01 INFUSION DEVICE FOR THE PREPARATION AND DELIVERY OF MRI PROBES US 63/328,556 Expired
NIDDK E-138-2017-0-JP-20 COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS JP DIV 2022-063285 Issued
NCI E-174-2019-0-US-04 A VIRAL EXPOSURE SIGNATURE FOR DETECTION OF EARLY STAGE HEPATOCELLULAR CARCINOMA US National Stage 17/766,015 Pending
NHGRI E-175-2019-0-US-04 SYNTHETIC GENES FOR THE TREATMENT OF PROPIONIC ACIDEMIA CAUSED BY MUTATIONS IN PROPIONYL-COA CARBOXYLASE BETA US National Stage 17/766,067 Abandoned
NHLBI E-143-2021-2-US-01 Transmural Refinement Of Inner Curvature Charge Concentration Device For Tissue Laceration US CIP 17/710,149 Pending
NCI E-233-2014-0-EP-10 Methods of Isolating T Cell Receptors Having Antigenic Specificity for a Cancer-Specific Mutation EP DIV 22166152.3 Pending
NEI E-227-2018-0-EP-07 Druggable Taraget to Treat Retinal Degeneration EP National Stage 20780525.0 Pending
NLM E-023-2023-0-US-01 Methylation-Dependent Enrichment Of DNA By Organism Of Origin US 63/326,073 Expired
NIAID E-233-2017-0-US-06 ASSAY FOR THE DETECTION OF ALPHA-SYNUCLEIN SEEDING ACTIVITY ASSOCIATED WITH SYNUCLEINOPATHIES US CON 17/708,560 12105101 Issued PDF
NCATS E-042-2022-0-US-01 SYNTHESIS OF DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS US 63/325,313 Expired
NCI E-021-2015-0-EP-36 Anti-CD70 Chimeric Antigen Receptors EP DIV 22164990.8 Pending
NIDDK E-067-2022-0-US-01 A3 ADENOSINE RECEPTOR POSITIVE ALLOSTERIC MODULATORS US 63/325,095 Expired
NCATS E-060-2017-3-US-03 Compositions And Methods For Identifying And Treating Dystonia Disorders US CON 17/706,461 Abandoned
NIAID E-073-2022-0-US-01 NEUTRALIZING ANTIBODIES TO HIV-1 ENV AND THEIR USE US 63/324,152 Expired
NIAID E-079-2022-0-US-01 BASE-COVERED HIV-1 ENVELOPE ECTODOMAINS AND THEIR USE US 63/324,121 Expired
NIAID E-080-2022-0-US-01 BISPECIFIC ANTIBODIES TO HIV-1 ENV AND THEIR USE US 63/324,037 Expired
NIAID E-060-2025-1-PC-01 Immunogenic Compositions PCT PCT PCT/EP2022/057945 Expired
NIAID E-060-2025-0-PC-01 Immunogenic Compositions PCT PCT PCT/EP2022/057933 Expired
NIDCR E-034-2021-0-US-01 Regulation Of Connexin Channels In The Inner Ear For Treating Deafness And Hearing Loss US 63/323,726 Expired
NCI E-022-2017-0-US-10 METHODS FOR SELECTING THERAPY FOR A CANCER PATIENT US CON 17/703,005 Abandoned
NEI E-227-2018-0-AU-03 Druggable Target to Treat Retinal Degeneration AU National Stage 2020346064 Pending
NIDDK E-086-2022-0-US-01 METHOD AND SYSTEM FOR SYNCHRONIZING A ROTATIONAL ECCENTRIC MASS WITH A MAGNETIC RESONANCE ELASTOGRAPHY SCAN US ORD 17/702,212 11821972 Issued PDF
NIDDK E-138-2017-0-CN-19 COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS CN DIV 202210281874.3 Abandoned
NCATS E-041-2021-1-US-01 RALDH1 Inhibitors For The Immunotherapy Of Hepatocellular Carcinoma US 63/321,682 Abandoned
NCI E-030-2022-0-AU-01 Anti-Viral Compositions And Methods Of Making And Using AU National Stage 2020346819 Pending
NIDDK E-001-2022-0-US-01 MOTOR FOR A MR ELASTOGRAPHY TRANSDUCER US ORD 17/697,492 11852704 Issued PDF
NCI E-097-2021-0-PCT-02 FLUOROGENIC CYANINE CARBAMATES PCT PCT PCT/US2022/020708 Expired
NCI E-176-2022-0-JP-01 Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease JP National Stage 2022-517823 Abandoned
NCI E-176-2022-0-KR-01 Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease KR National Stage 10-2022-7008878 Abandoned
NCI E-042-2014-0-US-33 CHIMERIC ANTIGEN RECEPTORS TARGETING CD-19 US CON 17/696,249 12473359 Issued PDF
NIAID E-081-2013-4-JP-21 Prefusion RSV F Proteins And Their Use JP DIV 2022-041006 Issued
NCATS E-039-2021-0-PCT-02 METHODS AND SYSTEMS FOR SOLID PHASE EXTRACTION PCT PCT PCT/US2022/020596 Expired
NCI E-176-2022-0-CA-01 Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease CA National Stage 3154761 Abandoned
NEI E-227-2018-0-ZA-14 Druggable Target to Treat Retinal Degeneration ZA National Stage 2022/03100 Pending
NCI E-111-2021-0-PCT-02 CANCER VACCINE AND METHOD OF USE THEREOF PCT PCT PCT/US2022/020165 Expired
NIAAA E-189-2021-0-US-01 CANNABINOID RECEPTOR MODULATING COMPOUNDS US 63/319,642 Expired
NCI E-042-2014-0-IL-34 Chimeric Antigen Receptors Targeting CD-19 IL DIV 1992-12-29 Pending
NCI E-182-2019-2-US-07 RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER US National Stage 17/692,978 12486270 Issued PDF
NCI E-181-2017-0-US-23 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS US DIV 17/692,787 12304940 Issued PDF
NIAID E-029-2007-0-US-05 RECOMBINANT VIRUS WITH DIMINISHED LATENCY AND METHODS OF USING SAME US DIV 17/692,540 12296004 Issued PDF
NEI E-227-2018-0-US-13 DRUGGABLE TARGET TO TREAT RETINAL DEGENERATION US National Stage 17/642,610 Pending
NEI E-227-2018-0-JP-10 Druggable Taraget to Treat Retinal Degeneration JP National Stage 2022-516237 Pending
NEI E-227-2018-0-CA-05 Druggable Taraget to Treat Retinal Degeneration CA National Stage 3151011 Pending
NEI E-227-2018-0-MX-12 Druggable Taraget to Treat Retinal Degeneration MX National Stage MX/a/2022/003027 Pending
NEI E-227-2018-0-BR-04 Druggable Taraget to Treat Retinal Degeneration BR National Stage BR112022004515-8 Pending
NCI E-075-2022-0-US-01 ANTIBODY MATERIALS AND METHODS TARGETING MICROBIAL POLYSACCHARIDES US 63/319,090 Expired
NCI E-266-2011-0-US-61 T CELL RECEPTORS RECOGNIZING HLA-A1-RESTRICTED MAGE-A3 US CON 17/691,569 12441778 Issued PDF